China-based Ascentage Pharma (HKG: 6855) announced the launch of a Named Patient Program (NPP) for its drug olverembatinib in partnership with US-based Tanner Pharma Group. The program aims to provide access to the drug in over 100 countries and regions where it is not yet commercially available.
Drug Profile
Olverembatinib is currently approved by the National Medical Products Administration (NMPA) for use in China for adult patients with tyrosine kinase inhibitor (TKI)-resistant chronic phase chronic myeloid leukemia (CML-CP) or accelerated-phase CML (CML-AP) with the T315I mutation, as confirmed by a validated diagnostic test.
Program Details
Named Patient Programs allow physicians to legally and ethically prescribe investigational or approved drugs to patients in need before commercial availability. Under the agreement, Tanner Pharma will supply olverembatinib to healthcare providers on a named patient basis in countries where the drug is not commercially available. The NPP is being launched globally to give patients the opportunity to access olverembatinib.
Tanner Pharma Group
Tanner Pharma Group, based in Charlotte, North Carolina, USA, with offices in Europe and Latin America, is a specialist pharmaceutical services provider. Through its Managed Access Programs division, Tanner supports manufacturers by providing ethical, controlled, and compliant access to innovative medicines in countries where they are not commercially accessible. The company has enabled patient access to medicines for over 20 years in more than 130 countries and has extensive experience supporting CML patients.-Fineline Info & Tech
